Edition:
United States

Baxter International Inc (BAX)

BAX on New York Consolidated

63.51USD
22 Sep 2017
Change (% chg)

$0.13 (+0.21%)
Prev Close
$63.38
Open
$63.48
Day's High
$63.75
Day's Low
$63.34
Volume
2,352,331
Avg. Vol
2,587,824
52-wk High
$64.75
52-wk Low
$43.13

Select another date:

Thu, Aug 31 2017

BRIEF-Baxter and MATTER Healthcare on patient-driven innovation

* Baxter and MATTER Healthcare Incubator Partner on patient-driven innovation

Big-name U.S. hedge funds shed healthcare stocks during the rally in second-quarter

NEW YORK Several big-name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U.S. stock market higher, rallying amid a Republican effort to repeal and replace President Obama's signature healthcare law.

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON, July 20 Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

BRIEF-Baxter appoints Cathy R. Smith to its board

* Appointed Cathy R. Smith, executive vice president and cfo of target corp, to its board ​

BRIEF-Baxter announces agreement with Dorizoe Lifesciences to further expand generic injectables pipeline

* Baxter announces agreement with dorizoe lifesciences to further expand generic injectables pipeline

BRIEF-Baxter announces U.S. FDA approval, commercial launch of ready-to-use clindamycin injection in saline

* Baxter announces U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline

BRIEF-Third Point Llc reports a stake of 7.5 pct in Baxter International

* Third Point Llc reports a stake of 7.5 percent in Baxter International as of June 1

BRIEF-Baxter and Mayo Clinic launch R&D collaboration to transform patient care

* Baxter and Mayo Clinic launch research and development collaboration to transform patient care

BRIEF-Third Point LLC dissolves share stake in Apple, Goldman Sachs

* Third Point LLC dissolves share stake in Apple Inc - sec filing

Select another date: